Study explores risk for shingles in the current era
|
|
- Esther Hart
- 5 years ago
- Views:
Transcription
1 CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study explores risk for shingles in the current era 19 February 2015 Infection with VZV (varicella zoster virus), a member of the herpes virus family, is relatively common. In general, in childhood VZV causes chickenpox and in adults it recurs to cause shingles. After the signs and symptoms of chickenpox resolve, VZV goes into a state of latent infection inside nerve cells. It is generally held in check by the immune system. However, as the immune system weakens with age, VZV can become reactivated, resulting in shingles (also called herpes zoster). Shingles is a painful skin condition that is most commonly seen in people over the age of 50. However, there are cases when the immune system becomes weakened, such as stress from another infection, that can allow the reactivation of VZV leading to shingles even in younger people. People dealing with the following health issues can also, sometimes, develop shingles: HIV infection cancer lupus type 2 diabetes organ transplant corticosteroid use Focus on HIV In the time before the availability of potent combination anti-hiv therapy (commonly called ART or HAART), rates of shingles were high among HIV-positive people. Fortunately, ART became available in high-income countries in 1996, and since then serious infections arising from weakened immunity are less common among people taking ART. HIV, ART and shingles To better understand trends in shingles cases as well as the impact of ART, researchers in Paris, France, analysed health-related information collected from both HIV-positive and HIV-negative people. They found that cases of shingles decreased significantly once ART became available in France in However, even after 1996, researchers found that HIV-positive people had a generally elevated risk for shingles. Shingles is relatively common in older people but in the French study HIV-positive people aged 15 to 44 years were at greatest risk for this condition. Study details Researchers reviewed health-related information collected from major clinics across France and centralized in the French Hospital Database (FHDB). The data from HIV-positive people were collected from 1992 to the end of Health-related information from HIV-negative people was collected between 2005 and The data for HIVnegative people was provided by a network of general practitioners (family doctors) called Réseau Sentinelles. This network reports any cases of certain diseases and conditions (including shingles) that occur in France. Other research has shown that this network is broadly reflective of the diseases and conditions that family doctors treat across France. Results Shingles
2 Researchers analysed data from 91,044 HIV-positive people and found that 7,167 had been diagnosed with shingles. Below is a brief average profile of HIV-positive people with shingles: 72% men, 28% women age 38 years CD4+ count 304 cells/mm 3 lowest-ever CD4+ count 176 cells/mm 3 proportion with an HIV viral load less than 500 copies/ml 29% Overall, researchers found that cases of shingles among HIV-positive people fell significantly once ART was introduced. Trends Gender Among HIV-positive people, there were always more cases of shingles in men than women. However, this difference decreased in more recent years. Rebuilding the immune system Untreated HIV infection significantly weakens the immune system. As a result, the immune system may not recognize some germs; even in cases when it does, the immune system may sometimes fail to produce an effective immune response against germs. This dysfunction allows germs to accumulate in the body. Once a person initiates ART their immune system begins to gradually improve its ability to detect germs and rapidly respond to them. Depending on the degree of pre-art immunological dysfunction and injury, during the first six months after initiating ART, immunological responses toward germs may not be ideal. IRIS People who have accumulated a high degree of immunological injury prior to initiating ART have an increased risk of inflammatory reactions in the first three months after initiating ART. Such reactions are called immune reconstitution inflammatory syndrome (IRIS). This occurs because the recovering immune system is still somewhat dysfunctional but thanks to ART it can now recognize germs and mount a response to attack them. The response is often exaggerated, perhaps partly driven by a high amount of a particular germ, perhaps driven in part by immunological dysfunction. Whatever the underlying reason, IRIS can cause tissue injury. Symptoms of IRIS can vary depending on the organ system affected and can range from mild fever and lack of energy to more serious symptoms that can resemble an infection. IRIS reactions are more common in people whose lowest pre-art CD4+ counts were less than 100 cells/mm 3. In all cases, IRIS is driven by an exaggerated inflammatory reaction to a germ. Doctors may prescribe anti-inflammatory agents such as the temporary use of corticosteroids to reduce the intensity of IRIS. Starting ART and shingles In the FHDB study, researchers noticed that after 1996 (when ART became available in France) cases of shingles would sometimes occur within three months of participants initiating ART. This is likely the result of participants initiating ART when their immune systems were weakened. Comparisons Among HIV-negative people in France, researchers found that half of people with shingles were 60 years or older. Also, shingles in this population was more common in women than in men. The researchers also found that, overall, HIV-positive people, regardless of gender, were generally three-fold more likely to develop shingles than HIV-negative people. The risk for shingles among HIV-positive people was greatest for people aged 15 to 44 years. In this group, the risk for shingles was six-fold greater than among HIV-negative people.
3 Once HIV-positive people reached the age of 65 years, their risk for shingles was similar to that of HIV-negative people. Due to the high risk of shingles among relatively young HIV-positive people, the French researchers stated that the benefits and safety of VZV vaccination should be studied in [this population]. They concluded their report by stating: Clinicians and patients should be aware that ART temporarily increases the risk of shingles during the first six months of treatment. About chickenpox and shingles Below is some brief information about these conditions. Chickenpox VZV, a member of the herpes virus family, causes chickenpox and shingles. Chickenpox was formerly a common childhood infection, but is now less common due to routine vaccination of all children in Canada and many high-income countries. In most cases, chickenpox results in a skin rash, low-grade fever and lack of energy. Generally, chickenpox itself is not life threatening. However, because the rash results in skin lesions that can be very itchy, affected children are prone to scratching them, which makes the underlying soft tissue susceptible to infection by bacteria that normally live on the skin. Such so-called secondary bacterial infections can be serious, rarely leading to flesh-eating disease" (necrotizing fasciitis) and/or toxic shock syndrome. Pneumonia and inflammation of the brain (encephalitis) can also be complications of chickenpox. According to the Public Health Agency of Canada (PHAC), complications are more common in adolescents, adults and people with conditions that compromise their immune system who have higher rates of pneumonia, encephalitis and death. It is also dangerous to infants whose mothers develop chickenpox around the time of delivery. The virus that causes chickenpox is easily spread through the air when people with chickenpox sneeze or cough. It can also be spread by touching the fluid that comes from chickenpox lesions and by kissing. A person with chickenpox is no longer contagious once all the skin lesions have crusted over. After signs and symptoms of chickenpox clear, the virus that causes it can go into a state of latency. Shingles Shingles occurs when latent VZV infection becomes reactivated. Although shingles can occur at any age, it is generally most common in adults who are 50 years and older. In general Shingles in adults initially appears as an intense tingling or burning pain on one side of the body. This pain is followed by the appearance of red patches and the formation of small sores. Blisters form and these eventually become crusted, dry and fall off. The pain and blisters are usually along the parts of the skin supplied by a single nerve that was latently infected with VZV which has reactivated. While scars from shingles are not common, older adults can sometimes develop persistent burning or tingling pain where their shingles appeared; this is called post-herpetic neuralgia and may require treatment. During shingles some people develop symptoms similar to a flu. An episode of shingles usually lasts for between one and two weeks. Shingles is not spread through the air like chickenpox, but can be spread when a person touches the fluid from a blister. Keeping blisters covered greatly helps to reduce the possible spread of shingles. People with shingles are not infectious before the appearance of blisters or after blisters have become crusted. In cases of weakened immunity In people with HIV and other immunological disorders, both chickenpox and shingles can take longer to clear, up to four weeks in some cases. What s more, shingles can recur in such people.
4 Treatment of shingles can include the antiviral drugs valacyclovir or famciclovir. These drugs can speed the healing of lesions and sometimes cause a reduction in pain and the risk for post-herpetic neuralgia. Although vaccines are licensed to reduce the risk of developing chickenpox and shingles, they contain weakened but live virus. People with HIV infection (or parents of children with HIV) should consult an infectious disease or HIV specialist about whether it is safe for them (or their children) to receive these vaccines. If someone with a weak immune system is in contact with a person infected with chickenpox, it is important that they contact their health care provider to find out if they need treatment to prevent developing chickenpox themselves. Research Two candidate shingles vaccines are being tested for possible use in people with immunological disorders. These vaccines are: a heat-treated vaccine this contains virus that has been treated with heat so that it cannot cause infection. However, it can stimulate immunity to VZV. This vaccine is being developed by Merck. a subunit vaccine this contains a protein from VZV that is coupled with a protein derived from bacteria. The purpose of the bacterial protein is to stimulate the immune system when it is exposed to the protein from VZV, amplifying the immune response to VZV. Neither the protein from VZV nor the protein from bacteria can cause infections. This vaccine is being developed by GlaxoSmithKline. Preliminary results from clinical trials of both of these vaccines suggest that they are safe and cause immunity to VZV. Resources About chickenpox About the chickenpox vaccine About shingles About the shingles vaccine Acknowledgement We thank infectious disease specialist Jason Brophy, MD, for his helpful comments, expert review and research assistance. REFERENCES: Sean R. Hosein 1. Whitley RJ. Chapter 180. Varicella-Zoster Virus Infections. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 18e. New York, NY: McGraw-Hill; Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurology Nov;6(11): Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clinical Infectious Diseases. 2015; in press. 4. Mary-Krause M, Grabar S, Lièvre L et al. Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). International Journal of Epidemiology Oct;43(5): Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: A phase 1/2a randomized, placebo-controlled study. Journal of Infectious Diseases. 2015; in pres s. 6. Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. Journal of Infectious Diseases Nov 1;208(9): Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Current HIV/AIDS Reports Sep;9(3): Martin-Blondel G, Mars LT, Liblau RS. Pathogenesis of the immune reconstitution inflammatory syndrome in HIVinfected patients. Current Opinion in Infectious Diseases Jun;25(3):
5
6 Produced By: 555 Richmond Street West, Suite 505, Box 1104 Toronto, Ontario M5V 3B1 Canada Phone: Toll-free: Fax: Charitable registration number: RR Disclaimer Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question. CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature. CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders. Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs. Permission to Reproduce This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at CATIE Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada. Available online at:
Long-acting drugs for HIV
From TreatmentUpdate 222 Long-acting drugs for HIV Long-acting formulations of two anti-hiv drugs are being tested in clinical trials: cabotegravir an experimental integrase inhibitor made available in
More informationViral infections Hep C and HIV linked to hip fractures
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Viral infections Hep C and HIV linked to hip fractures 22 November 2012 Infection with hepatitis C virus (HCV) and HIV causes inflammation,
More informationDetailed results from the START study
From TreatmentUpdate 210 Detailed results from the START study Researchers in 35 countries across all continents collaborated to recruit 4,685 HIV-positive adults who were in good health for START. Upon
More informationUnderstanding risk by sex act
From Safer Sex Guide Understanding risk by sex act Kissing (with tongue) Chlamydia Avoid kissing if you or your partners have sores on the lips or mouth, or if one of you has an active oral infection (such
More informationFrom Safer Sex Guide. Using condoms
From Safer Sex Guide Using condoms Click to enlarge Using condoms correctly and consistently can signifiantly reduce your chances of passing or getting HIV and other STIs. There are two types of condoms
More informationNorthern Alberta preventing HIV transmission to babies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Northern Alberta preventing HIV transmission to babies 25 June 2009 Since 1996 the widespread availability of combination therapy for HIV
More informationPatient navigators for hepatitis C patients found useful in New York City
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Patient navigators for hepatitis C patients found useful in New York City 4 January 2017 Hepatitis C virus (HCV) infects and injures the
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationThe debut of velpatasvir for hepatitis C
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The debut of velpatasvir for hepatitis C 23 November 2015 Hepatitis C virus (HCV) can be grouped into six major strains, or genotypes,
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationHere are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Alberta Reducing deaths by strengthening the HIV Treatment Cascade 20 May 2014 In Canada and other high-income countries, deaths from AIDS-related
More informationNorwegian HIV vaccine Very modest results seen in recent clinical trial
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Norwegian HIV vaccine Very modest results seen in recent clinical trial 21 February 2012 Although HIV infection can be treated with combination
More informationA study about switching from TDF to TAF
From TreatmentUpdate 211 A study about switching from TDF to TAF Researchers enrolled HIV-positive participants who were taking regimens containing TDF (tenofovir disoproxil fumarate), the original formulation
More informationHepatitis C treatment program improves access to housing, income and healthcare
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hepatitis C treatment program improves access to housing, income and healthcare 13 July 2015 Despite high rates of hepatitis C virus (HCV)
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More informationHow are testing technologies used to diagnose HIV infection?
HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,
More informationStudy finds sustained-release dexamfetamine is promising for reducing cocaine use
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study finds sustained-release dexamfetamine is promising for reducing cocaine use 27 April 2016 Depending on the circumstances, the use
More informationThe epidemiology of HIV in Canada
FACTSHEET The epidemiology of HIV in Canada This fact sheet provides a snapshot of the HIV epidemic in Canada. It is one of a series of fact sheets on the epidemiology of HIV and hepatitis C in Canada.
More informationThe epidemiology of hepatitis C in Canada
The epidemiology of hepatitis C in Canada FACT SHEET Published 2017 This fact sheet provides a snapshot of the hepatitis C epidemic in Canada. It is one of a series of fact sheets providing epidemiological
More informationIncreased risk for dialysis found with HIV infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Increased risk for dialysis found with HIV infection 12 September 2013 In high-income countries such as Canada, Australia and the U.S.
More informationIs there a link between niacin and stroke?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Is there a link between niacin and stroke? 7 July 2011 A large American-Canadian study called Aim-High was halted 18 months ahead of schedule.
More informationIt is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.
FACTSHEET Sexually Transmitted Infections and HIV Transmission This is one of a series of fact sheets about the biology of HIV transmission. The fact sheets review specific biological factors that make
More informationHIV testing technologies
HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including
More informationExploring risks for MRSA infection A tale of two studies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring risks for MRSA infection A tale of two studies 2 March 2012 A group of bacteria called S. aureus (Staphylococcus aureus ) are
More informationKey messages on hepatitis A for clients are available at the end of this fact sheet.
Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is transmitted
More informationHIV and the immune system linked to heart disease in women
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. HIV and the immune system linked to heart disease in women 26 September 2013 The widespread availability of potent combination anti-hiv
More informationLimiting the spread of hepatitis C virus with Treatment as Prevention (TasP)
From TreatmentUpdate 197 Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) The idea of Treatment as Prevention, or TasP, has been proposed and is being implemented in some regions
More informationDoes syphilis affect HIV in the brain?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does syphilis affect HIV in the brain? 1 February 2011 Outbreaks of sexually transmitted infections (STIs) are occurring in Canada and
More informationHepatitis A FACTSHEET. Summary. What is hepatitis A?
FACTSHEET Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is
More informationSuperbug increasing among HIV positive people
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Superbug increasing among HIV positive people 24 September 2007 Bacteria are a common source of problems, causing a variety of infections,
More informationTuberculosis FACT SHEET. Summary. What is TB?
Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts of the body
More informationAmerican Academy of Pediatrics issues statement on infant feeding and HIV transmission
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. American Academy of Pediatrics issues statement on infant feeding and HIV transmission 7 February 2013 The widespread availability of potent
More informationTuberculosis FACTSHEET. Summary. What is TB?
FACTSHEET Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts
More informationApproximately 25% of people develop shingles during their lifetime, with the majority of cases occurring in those over 50 years of age.
ÜNZÜLE ALPASLAN WHAT IS SHINGLES? Shingles is an infection of an individual nerve and the skin surface that is supplied by the nerve; it is caused by the varicella-zoster virus - the same virus that causes
More informationPost-exposure prophylaxis (PEP)
Post-exposure prophylaxis (PEP) Summary Post-exposure prophylaxis, or PEP, is a way to help prevent the transmission of HIV in an HIV-negative person who may have been recently exposed to HIV. It involves
More informationHep C treatment can cure a person from Hep C. However, a person could get infected again.
Sofosbuvir (Sovaldi) Summary Sofosbuvir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. Sofosbuvir is taken at a dose of 400 mg
More informationTHE POWER OF UNDETECTABLE. What you need to know about HIV treatment as prevention
THE POWER OF UNDETECTABLE What you need to know about HIV treatment as prevention CONTENTS 3 Treatment as prevention First, a few basics: What is an undetectable viral load? How do I know if I m undetectable?
More informationProf Dr Najlaa Fawzi
1 Prof Dr Najlaa Fawzi is an acute highly infectious disease, characterized by vesicular rash, mild fever and mild constitutional symptoms. is a local manifestation of reactivation of latent varicella
More informationDoes tenofovir (TDF) cause liver injury?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does tenofovir (TDF) cause liver injury? 10 February 2016 Tenofovir is an important antiviral drug used to treat HIV and hepatitis B virus
More informationHepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE
Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C
More informationStarting points. living with HIV
Starting points living with HIV Have you found out you have HIV and are trying to get your bearings? We can help you with the basics of living with HIV. Here s what you ll read about in this booklet: What
More informationRaltegravir (Isentress)
Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Raltegravir is generally well tolerated. Common side effects include diarrhea, nausea and headache;
More information3TC (lamivudine, Epivir)
3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes few side
More informationAged 70 or 78? There s a vaccine to help protect you from the pain of shingles
Aged 70 or 78? There s a vaccine to help protect you from the pain of shingles This leaflet describes shingles and the benefits of the vaccination and who is eligible for the vaccine this year. There is
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationAged 70 or 78? There s now a vaccine to help protect you against shingles
Aged 70 or 78? There s now a vaccine to help protect you against shingles This leaflet describes shingles and the benefits of the vaccination. The new shingles vaccine is being phased in over the next
More informationThe Patient as Partner
From The Positive Side, Summer 2018 The Patient as Partner The idea that a person should be an active participant, not just a recipient, of their own healthcare has deep roots. Feminists, people living
More informationChickenpox Notification
Goolwa Campus: (08) 8555 7500 Victor Harbor Campus: (08) 8551 0900 Investigator College Chickenpox Notification Date for Distribution: 2018 Dear Parents/Caregivers There has been a case of chickenpox reported
More informationCan metformin also protect arteries?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can metformin also protect arteries? 8 December 2011 Reports suggest that cardiovascular disease is becoming common among HIV-positive
More informationLymphoma FACTSHEET. Summary. About the lymphatic system. Who is at risk for lymphoma? What is lymphoma?
FACTSHEET Lymphoma Summary Lymphoma is a cancer that affects a part of the immune system called the lymphatic system. Like any cancer, the earlier lymphoma is diagnosed, the easier it is to treat. In general,
More informationShingles. A Guide to Understanding Herpes Zoster. By Sarah Weis, PharmD Candidate 2012
Shingles A Guide to Understanding Herpes Zoster Information Every Elder Should Know By Sarah Weis, PharmD Candidate 2012 Herpes zoster, also known as shingles, effects up to 1 million people every year
More informationExciting results in monkeys lead to a clinical trial in humans
From TreatmentUpdate 219 Exciting results in monkeys lead to a clinical trial in humans A close relative of HIV called SIV (simian immunodeficiency virus) causes an AIDS-like disease in susceptible monkeys.
More informationThere s a vaccine to help. protect you from the pain of. shingles. the safest way to protect your health
There s a vaccine to help protect you from the pain of shingles the safest way to protect your health There is a vaccine that helps reduce your risk of getting shingles and reduces the severity of symptoms
More informationShingles: Good Practice Guide. Advice and guidance on how to improve shingles vaccination uptake
Shingles: Good Practice Guide Advice and guidance on how to improve shingles vaccination uptake Shingles Shingles, also known as herpes zoster, is caused by the reactivation of a latent varicella zoster
More informationThere s now a vaccine to help protect you against. shingles. the safest way to protect your health
There s now a vaccine to help protect you against shingles the safest way to protect your health There is now a vaccine that helps reduce your risk of getting shingles and reduces the severity of symptoms
More informationWOMENCARE. Herpes. Source: PDR.net Page 1 of 8. A Healthy Woman is a Powerful Woman (407)
WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Herpes Basics: Herpes is a common viral disease characterized by painful blisters of the mouth or genitals. The herpes simplex virus (HSV) causes
More informationAntiviral medications can reduce the severity and frequency of genital herpes outbreaks.
Genital herpes Summary Genital herpes is a sexually transmitted infection caused by the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). Once a person is infected with HSV, the virus stays in the
More information3TC (lamivudine, Epivir)
FACTSHEET 3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes
More informationTo provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More informationIMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C
IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C GETTING STARTED: Important things to know when you have hepatitis C If you just found out that you have hepatitis C, you may have a lot of questions.
More informationCan mirtazapine assist recovery from crystal meth addiction?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can mirtazapine assist recovery from crystal meth addiction? 20 December 2011 Stimulants such as amphetamine and its more potent form,
More informationLesson 3: Immunizations
K-W-L Graphic Organizer K (Know) What do you know about W (Want) What do you want to know about L (Learned) What did you learn about Glossary 1. antibodies: proteins created by the immune system to fight
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Amar PP,, 2014; Volume 3(3): 123-127 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE A REVIEW ON HERPES ZOSTER AMAR PP 1, AJINKYA C 2, TOHID NB 2, ROHIDAS P 2, AVINASH C 2 1. Assistant
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationIn Canada and around the world, the trend is clear: sexually transmitted infections (STIs) are on the rise.
Adapted From: Sexually Transmitted Infections Pamphlet. Public Health Agency of Canada, 2007 In Canada and around the world, the trend is clear: sexually transmitted infections (STIs) are on the rise.
More informationSchizophrenia and HIV Study underscores serious issues associated with dual diagnoses
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses 15 July 2015 Several studies have found that some
More informationVARICELLA. Dr Louise Cooley Royal Hobart Hospital
VARICELLA Dr Louise Cooley Royal Hobart Hospital Varicella Zoster Virus (VZV): The Basics Herpes virus Exclusively human infection Primary infection: varicella (chickenpox) Neurotropic, establishing latency
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationDisseminated shingles acyclovir
Disseminated shingles acyclovir The Borg System is 100 % Disseminated shingles acyclovir Two developed disseminated herpes zoster, one developed cytomegalovirus. Reduced response to acyclovir,. Disseminated
More informationDaclatasvir (Daklinza)
Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in Canada for
More informationSection 10.5 Varicella
Section 10.5 Varicella Chickenpox Introduction Transmission Signs and Symptoms Complications Diagnosis Treatment Infection Prevention and Control Precautions for Residents with Chickenpox Additional considerations
More informationHepatitis C virus some background information
From TreatmentUpdate 167 Hepatitis C virus some background information Hepatitis C virus (HCV) is spread by exposure to infected blood. The following behaviours, which can expose a person to infected blood,
More informationToxoplasmosis FACT SHEET. What is toxoplasmosis? Symptoms CONTACT US. Published 2016
Toxoplasmosis What is toxoplasmosis? Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii (T. gondii). The parasite is transmitted to people through eating undercooked meat, especially
More informationSexually Transmitted Infections
Sexually Transmitted Infections STI Director/ Centers for Disease Control Overview Definition of STIs: What are they? Transmission: How are they spread? Types of infection: -Bacterial (Chlamydia, LGV,
More informationBy: Zenessa Morrison and Denise Bailey
By: Zenessa Morrison and Denise Bailey Shingles which is also known as Herpes Zoster is a painful skin rash caused by the Varicella virus. The Varicella virus belongs to the herpesviridae family. The structure
More informationSexually Transmitted Infections (STIs)
Sexually Transmitted Infections (STIs) Overview Definition of STIs: What are they? Transmission: How are they spread? Types of infection: Bacterial (Chlamydia, Gonorrhea, Syphilis) Viral (Hepatitis B,
More informationChildhood Contagious Diseases)5(
Childhood Contagious Diseases)5( Children have maturing immune systems and are often in close proximity to one another, such as in day-care centers, classrooms, and on school buss. This makes the transmission
More informationQuad (Stribild) Safety and effectiveness issues in depth
From TreatmentUpdate 191 Quad (Stribild) Safety and effectiveness issues in depth The FDA reviewed health-related information collected from 1,408 HIV-positive people who participated in two pivotal clinical
More informationAged 70 or 79? There is now a vaccine to help protect you against shingles
Aged 70 or 79? There is now a vaccine to help protect you against shingles Shingles affects a lot of people as they get older. It often causes severe pain which can last for months or sometimes years.
More informationNorovirus in Healthcare Settings
ST. JAMES HEALTHCARE DECEMBER 2012 INFECTION PREVENTION NEWSLETTER INSIDE THIS ISSUE: Norovirus in Healthcare Settings The Impacts of Unsafe Medical Injections in the U.S. Preparing Your Skin Before Surgery:
More information12. HIV-related infections and cancers
From Managing your health: a guide for people living with HIV 12. HIV-related infections and cancers Contents [hide] Life-threatening infections Co-infections Other infections Vaccinations Cancers Resources
More informationChickenpox Procedure. (IPC Policy Manual)
Chickenpox Procedure (IPC Policy Manual) DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Policy Approval Group Date ratified: 3 July 2018 Name of originator/author: Senior Clinical Nurse Specialist
More informationThe elusive AIDS vaccine
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The elusive AIDS vaccine 4 March 2008 In the 25 years since HIV was discovered, researchers have made many strides in the fight against
More informationHarvoni (ledipasvir + sofosbuvir)
Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. Harvoni is a combination of
More informationProgramming Connection
The H.E.R. Pregnancy Program Programming Connection Case Study Organization: Streetworks Region: Edmonton, Alberta Prepared: 2018 Quick Facts Population Street involved, Women Date Started 2011 Region
More informationHints of a cure the future of stem cell transplants and HIV
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hints of a cure the future of stem cell transplants and HIV 21 December 2010 In 2008 a team of cancer researchers from Berlin, Germany,
More informationDepartment of Health. Year 8. vaccination program. Important information for parents and students
Department of Health Year 8 vaccination program Important information for parents and students Contents Why immunise? 1 Vaccination program 1 Schedule of vaccinations 2 Vaccination records 2 Vaccine safety
More informationShingles (Herpes zoster)
Shingles (Herpes zoster) Introduction When the itchy red spots of childhood chickenpox disappear and life returns to normal, the battle with the virus that causes chickenpox seems to be won. But for all
More informationAcyclovir for ear infections
Acyclovir for ear infections The Borg System is 100 % Acyclovir for ear infections User feedback about Acyclovir side effects covering chicken pox, fatigue, shingles, hair loss, HSV2, dosage, anemia, ear
More informationCounty of Santa Cruz. General Questions About Measles HEALTH SERVICES AGENCY. Public Health Division. What is measles?
County of Santa Cruz Public Health Division HEALTH SERVICES AGENCY POST OFFICE BOX 962, 1080 EMELINE AVE., SANTA CRUZ, CA 95060 TELEPHONE: (831) 454-4000 FAX: (831) 454-4770 General Questions About Measles
More informationThe HIV testing process
FACTSHEET The HIV testing process Summary There are a few steps that a person will take in the HIV testing process. To access an HIV test, people can request a test or may be offered a test. There are
More informationHow It Spreads Symptoms Can Include Complications
OUR BEST SHOT: The Importance of Vaccines for Older Adults VACCINES QUICK GUIDE TO VACCINATION FOR ADULTS AGES 60+ Vaccines are an important step in protecting your health and the health of your family.
More informationWill de-simplification of HIV treatment become common in highincome
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Will de-simplification of HIV treatment become common in highincome countries? 13 February 2018 As more people start HIV treatment, researchers
More informationThe Ministry of Health recommends measles vaccines for all child care providers, children and parents to ensure they are protected against measles.
Since January 1, 2014, there have been several cases of measles reported in Saskatchewan. Because measles is a highly contagious vaccine-preventable disease and there are a number of unvaccinated children
More informationIn the Republic of Ireland, side effects can be reported online at or directly to the HPRA by calling (01)
MAVENCLAD 10 mg Tablets (cladribine) Patient Guide IMPORTANT INFORMATION ON MINIMISING THE RISK OF ADVERSE EVENTS Reporting of side effects If you get any side effects, talk to your doctor, pharmacist
More informationMG an emerging sexually transmitted infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. MG an emerging sexually transmitted infection 9 October 2013 The bacterium Mycoplasma genitalium (MG) is sexually transmitted and can cause
More informationWhat Does HIV Do to You?
What Does HIV Do to You? HIV and the immune system Your immune system is supposed to protect you from viruses and other infections. Why, then, doesn t it protect you from HIV? The answer is complicated,
More informationI ANTI-HIV AGENTS. Contents I ANTI-HIV AGENTS II COMPLICATIONS AND SIDE EFFECTS. A. Raltegravir vs. efavirenz four. years later
TreatmentUpdate 179 Vol. 22, No. 4 May/June 2010 ISSN 11817187 Available on the World Wide Web at www.catie.ca/tu.nsf Contents I ANTI-HIV AGENTS A. Raltegravir vs. efavirenz four years later 1 B. Raltegravir
More informationHarvoni (ledipasvir + sofosbuvir)
FACTSHEET Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with genotype 1 hepatitis C virus. Harvoni is a combination of
More information